Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Next Step for NYSE Euronext (NYX)

Page 1 of 2

As the company behind the prestigious New York Stock Exchange, NYSE Euronext (NYSE:NYX) makes money when people trade any stock. Yet for its own part, NYSE Euronext stock has soared in anticipation of its pending $8.2 billion acquisition by rival IntercontinentalExchange Inc (NYSE:ICE). With European regulators having approved the deal earlier this week, the transaction appears to be on track to close during the second half of the year, although the SEC and other regulators have yet to weigh in. Let’s take a closer look at the exchange industry and what shareholders in NYSE Euronext (NYSE:NYX) can expect going forward.


Understanding the ICE deal
If you own NYSE Euronext (NYSE:NYX) stock, the ICE buyout gives you choices about what you’ll receive in exchange for your shares. With the transaction valued at $33.12 per share at the time of the offer in late December, shareholders will have the election of receiving cash or IntercontinentalExchange Inc (NYSE:ICE) shares, with 25.81 shares of ICE stock for every 100 shares of NYSE Euronext stock you own. The election is subject to maximum cash and stock requirements that ICE set, with an overall mix of two-thirds stock and one-third cash. Due largely to the fact that ICE shares have posted strong gains, the stock price for NYSE Euronext (NYSE:NYX) has climbed well above the $33.12 level.

Shareholders already approved the deal earlier this month, so what shareholders are waiting for are customary approvals from regulators looking at potential anti-competitive effects and other financial considerations. Given the big role that exchanges play in the financial markets, regulatory examinations are especially important, but so far, the companies haven’t seen any roadblocks to their merger.

The crown jewel of the trading world
One of the biggest concerns about the NYSE Euronext (NYSE:NYX) takeover is preserving the long history of the New York Stock Exchange. Even though technology has greatly transformed how stocks actually trade, the culture of the NYSE still stands as a testament to the importance of live human beings in conducting trading and making markets. ICE has committed to preserving the NYSE brand, maintaining a corporate presence in the same building that houses the NYSE trading floor.

Yet the importance of the NYSE has fallen in recent decades, as rival exchanges have risen up to compete not just in the U.S. but globally as well. Rival NASDAQ OMX Group, Inc. (NASDAQ:NDAQ) represents the obvious competitive threat in U.S. stocks, with recent moves like opening up shorter ticker symbols to Nasdaq-traded companies helping the exchange close a gap with the NYSE. Yet so-called dark pools have taken away a considerable amount of volume from the major exchanges as well, as computer-driven traders seek advantages from other trading venues.

Among exchanges, the action is beyond the stock market. With the rise in trading of futures, options, and other derivative investments, NYSE Euronext’s ownership of the NYSE Liffe exchange in London was a key element of ICE’s interest. CME Group Inc (NASDAQ:CME) and CBOE Holdings, Inc (NASDAQ:CBOE) have worked hard to preserve their respective strength in futures and options, and rising market turbulence has made many of their products look a lot more enticing. Given that derivatives can help hedge market risk and reduce overall exposure, all of the exchange companies have an opportunity to bolster their presence in the derivatives market with innovative products that meet the new needs investors have in a more turbulent financial environment.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!